Degree of Alignment Between Japanese Patients and Physicians on Alopecia Areata Disease Severity and Treatment Satisfaction: A Real-World Survey
ConclusionsThis study highlights previously unreported patient-physician misalignment on disease severity, level of treatment dissatisfaction and unmet needs due to the lack of effective treatment. Further study on how improvement of the misalignment between physicians and patients could increase both patient and physician satisfaction with treatment and improve the quality of life for patients with AA. (Source: Dermatology and Therapy)
Source: Dermatology and Therapy - December 11, 2023 Category: Dermatology Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
LITFULO < sup > TM < /sup > (Ritlecitinib) Capsules: A Janus Kinase 3 Inhibitor for the Treatment of Severe Alopecia Areata
Skinmed. 2023 Dec 5;21(6):434-438. eCollection 2023.ABSTRACTLITFULOTM (ritlecitinib) capsules were recently approved for the treatment of severe alopecia areata in adolescents and adults, aged ≥12 years. Ritlecitinib is the active ingredient and a dual inhibitor of Janus kinase 3 and the tyrosine kinase expressed in hepatocellular carcinoma kinase family. It prevents immune attack on the hair follicles that leads to hair loss. In a phase 2b-3 dose-dependant study, five doses of oral ritlecitinib and placebo administered once daily (QD) were investigated. Ritlecitinib demonstrated efficacy in achieving the primary outcome...
Source: Skinmed - December 5, 2023 Category: Dermatology Authors: Aditya K Gupta Shruthi Polla Ravi Kimberly Vincent William Abramovits Source Type: research
International Dermatology Outcome Measures (IDEOM) - Report from the 2022 Annual Meeting
This report summarizes each workgroup's updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting. J Drugs Dermatol. 2023;22(12):1153-1159 doi:10.36849/JDD.7615.PMID:38051841 | DOI:10.36849/JDD.7615 (Source: Journal of Drugs in Dermatology)
Source: Journal of Drugs in Dermatology - December 5, 2023 Category: Dermatology Authors: Kathryn Lee Michael J Woodbury Melissa Peri Zundell Rosario Aguero Jenna Yousif Samuel Clay Williams David Rosmarin Nanette Silverberg Diane Thiboutot Cecilia Larocca Michi M Shinohara Arash Mostaghimi Sonja Stander Antonio Martorell Tarannum Jaleel Richa Source Type: research
